Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (1375)	11/3/1999 7:40:00 PM
From: Street Walker	Read Replies (3) \| Respond to of 5582

ZICAM -------- PRODUCTION CAPACITY Current production capacity is 200,000 units/week. They had to line up 3 other manufactures for over flow production. After all is said and done (taking into account the 60% ownership of Zicam, etc) GUMM makes a NET PROFIT of around $1.75 per sale !! Huge profit margin! A local visit to stores: Rite Aid --- they are SOLD OUT. They contacted their wholesaler and the WHOLESALER is SOLD OUT. They have made a humongous order to get the wharehouses stocked. Costco They are selling 20 per day ! It is so popular the manager is going to place one of those huge cases in a main section where more customers can see it, along with the cases in the pharmacy area. He is getting reports that throughout the very large city, all the competing stores are SOLD OUT OF ZICAM. ZICAM is the NUMBER ONE remedy for the common cold. It is a huge medical breakthough. $2.5 BILLION was spent on OTC cold remedies last year. ZICAM is going to overtake the market ! The growth potential is for real. Given a very small float and shares outstanding, GUMM will trade at $100+ in twelve months, split adjusted. Past Earnings: 4th quarter 98: loss of 29cents !! ouch !! 1st quarter 99: loss of around 8 cents 2nd quarter 99: loss of 10 cents/share. 3rd quarter 99: ESTIMATES range between a loss of 4 to 5 cents Prior financial statements are of no consequence. The future GROWTH of this number 1 product is the investment. Each year ZICAM will penetrate further and further into the $2.5 BILLION USA market I can't wait to see the growth ZICAM will have when it is launched INTERNATIONALLY next year. Regards, S.W.